B+
Bull case
20%
Probability
Target price
$55.00
+671.4% vs current
LENZ
LENZ TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$13.00
+82.3% vs current
B-
Bear case
20%
Probability
Target price
$6.00
-15.8% vs current
AI sentiment snapshot
Latest data as of 2026-03-25
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Market commentary around the March 24 earnings and press release was mixed: some focus on early commercial revenue while others flagged elevated expenses and execution risk [#8-K-2026-03-24][#PR-2026-03-17]. Investor sentiment is cautious-to-constructive given commercialization has begun but pipeline milestones remain the primary longer-term value drivers [#IR-undated].
RankAlpha Sentiment AI - 2026-03-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-23catalystCommercial uptake trajectory and early revenue cadence for VIZZ (aceclidine)High impact
Market reaction to initial commercial uptake metrics and Q1 sales cadence following the Q4/FY2025 results disclosure; company has positioned VIZZ as a commercial product in filings and IR materials [#10-K-2026-03-24][#IR-undated][#8-K-2026-03-24].
2027-03-25catalystProgress / readout milestones for LNZ100 / LNZ101 Phase 3 developmentHigh impact
Advancement and enrollment updates (and eventual pivotal readout window) for the company's LNZ100/LNZ101 presbyopia programs — pipeline and Series B financing referenced in company PR/IR; meaningful positive readout or enrollment acceleration would be a multi-quarter upside driver [#IR-undated][#PR-2026-03-17].
Recommendation
N/A
No formal recommendation provided.
As of 2026-03-25 • Updated nightlySource: Internal modelMethodology